US startup Helex raises $3.5m to advance preclinical kidney program
- By IndiaStartupBuzz | October 31, 2025
Helex, an innovative US-based biotech startup focused on kidney health, has raised $3.5 million in a fresh funding round to accelerate the development of its preclinical kidney program. The funding will support advancing Helex’s novel therapeutic candidates aimed at treating progressive kidney diseases, which remain a major unmet medical need worldwide.
Founded by scientists and clinicians passionate about transforming kidney care, Helex is developing targeted interventions to slow or reverse kidney damage in chronic kidney disease (CKD) patients. Its proprietary technology platform utilizes cutting-edge molecular biology to identify and modulate key pathways driving kidney fibrosis and inflammation.
The preclinical program, currently progressing through animal model studies, aims to demonstrate safety and efficacy markers necessary for eventual human clinical trials. By focusing on early-stage kidney disease mechanisms, Helex seeks to provide new treatment options that can reduce the need for dialysis or kidney transplant.
The latest $3.5 million capital infusion was led by eminent early-stage biotech investors, with participation from healthcare-focused venture funds and angel investors who recognize the huge market potential and medical impact. This seed financing will enable Helex to expand its research team, optimize lead compounds, and engage in regulatory planning.
Kidney disease affects over 850 million people globally, with chronic kidney failure causing significant morbidity and mortality. Despite the prevalence, current therapies largely manage symptoms rather than addressing root causes. Helex’s approach could shift this paradigm by targeting critical molecular drivers.
CEO and co-founder of Helex emphasized the company’s dedication to advancing its pipeline rapidly to answer the urgent need for innovative kidney therapeutics. The startup is currently exploring collaborations with academic institutions and pharmaceutical partners to further develop and commercialize its candidates.
The $3.5 million funding round positions Helex to make major strides in preclinical development within the next 12-18 months, with long-term goals of entering Phase 1 clinical trials and ultimately improving outcomes for millions suffering from kidney disease.
As kidney health garners increasing attention in the biotech investment community, Helex stands out through its focused scientific strategy and early progress, heralding a hopeful future in nephrology drug development.
